Condition
Kidney Cancer Clinical Trials
Studies of kidney cancer, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 565Renal Tumor Histology, Cutaneous Leiomyoma
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors.
- Conditions
- Renal Tumor Histology, Cutaneous Leiomyoma, Kidney Cancer
- Trial name
- NCT00050752
- Where
- United States
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in…
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
- Trial name
- SAMURAI (NCT05327686)
- Testing
- Avelumab, Axitinib, Biospecimen Collection
- Where
- 348 sites in United States, Australia and 2 more
- Volunteers
- 240 people
- Sponsor
- NRG Oncology
RCC, Renal Cell Carcinoma
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.
- Trial name
- NCT05931393
- Testing
- Cabozantinib 80 MG
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Texas Southwestern Medical Center
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract…
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma
- Trial name
- NCT05987241
- Testing
- Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography
- Where
- 503 sites in United States, Canada
- Volunteers
- 992 people
- Sponsor
- National Cancer Institute (NCI)
Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
This phase II trial studies how well ivonescimab works prior to surgery in treating patients with high-risk clear cell kidney (renal cell) cancer that has not spread to other parts of the body (localized).
- Conditions
- Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT07226544
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Advanced Renal Cell Carcinoma (RCC)
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)
- Trial name
- NCT07293351
- Testing
- Pumitamig, Ipilimumab, Cabozantinib
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 474 people
- Sponsor
- Bristol-Myers Squibb
Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies.
- Conditions
- Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
- Trial name
- NCT07419841
- Testing
- CTX-10726
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Compass Therapeutics
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 581 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Renal Cell Carcinoma Stage I
An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With Everolimus
This single-arm exploratory study included patients with renal clear cell carcinoma who had previously received one type of immunotherapy and failed. The specific regimen was Vorolanib 200mg PO.QD combined with everolimus 5mg QD.
- Trial name
- NCT06730672
- Testing
- Vorolanib combined with Everolimus Formation
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University